Halozyme Therapeutics Inc. company profile: Financials, acquisitions, and more

Business description

Halozyme Therapeutics Inc., founded in 1998 and headquartered in San Diego, California, develops and commercializes its proprietary ENHANZE enzyme technology to enable subcutaneous delivery of large molecule therapeutics. The company’s revenue is driven by royalties and milestone payments from partnerships with leading pharma companies. Led by CEO Paul Clancy since 2021, Halozyme is expanding its pipeline with new studies in oncology and immunology while strengthening its market position through strategic collaborations.

01 Explore

Everything on Halozyme Therapeutics Inc.

Financials

View financials

Revenue (FY2025) $1.40B

YoY growth +37.6%

Operating margin 33.6%

Direction Expanding

Gross margin 83.6%

Net margin 22.7%

Earnings Transcripts

View all transcripts

Q1 2026 View transcript Q4 2025 View transcript Q3 2025 View transcript Q2 2025 View transcript

Leadership & board

View leadership

Helen I. TorleyPresident and Chief Executive Officer; Director

Jeffrey W. HendersonBoard Chair; Director

Bernadette ConnaughtonDirector

Matthew L. PosardDirector

Barbara DuncanDirector

Mahesh KrishnanDirector

James LangDirector

Moni MiyashitaDirector

Nicole LaBrosseSenior Vice President, Chief Financial Officer

Mark SnyderSenior Vice President, Chief Legal Officer

Cortney CaudillSenior Vice President, Chief Operating Officer

Michael J. LaBarreFormer Senior Vice President, Chief Technical Officer

Acquisitions

View full breakdown

Halozyme Therapeutics acquires Antares Pharma, Inc.Drug delivery and specialty pharmaceuticals (auto injector platform + testosterone replacement therapy) · 2022 View full deal Halozyme Therapeutics acquires Elektrofi, Inc.Drug delivery technology (ultra-high concentration microparticle formulation for biologics) · 2025 View full deal

Share repurchases

In February 2024 the Board authorized a $750.0 million capital return program to repurchase common stock; as of September 30, 2025 a third $250.0 million tranche was underway with $92.3 million of it used, and the FY2025 cash-flow statement reported $342.4 million of common stock repurchased.

$750.0 million

Authorized

$157.7 million

Remaining

$342.4 million

Repurchased (latest FY)

Competitors

Named competitors

Amphastar Pharmaceuticals, Inc.Alteogen Inc.AbbViePerrigoLillyEndo, Inc.TevaViatrisScandinavian Health Ltd.Ypsomed AGWest PharmaceuticalOwen Mumford Ltd.

Recent SEC filings

View on EDGAR

2026-05-11 Reported quarterly results View filing ↗

2026-05-07 Shareholder vote results View filing ↗

2026-04-30 Leadership change (directors/officers) View filing ↗

2026-04-24 Amended charter/bylaws View filing ↗

2026-03-12 Leadership change (directors/officers) View filing ↗

2026-02-17 Reported quarterly results View filing ↗

2026-01-28 Reported quarterly results View filing ↗

2025-12-09 Leadership change (directors/officers) View filing ↗

2025-12-08 Leadership change (directors/officers) View filing ↗

2025-11-24 Leadership change (directors/officers) View filing ↗

2025-11-12 Entered a material agreement (+2 more) View filing ↗

2025-11-07 Other event View filing ↗